Codagenix, Inc., and the Serum Institute of India Pvt. Ltd. (SIIPL) have announced that a Phase 1 clinical trial of COVI-VAC received regulatory approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) and has commenced in London, United Kingdom.
COVI-VAC is a single-dose intranasal, live attenuated vaccine against SARS-CoV-2, the virus that causes Covid-19, that was proved to be safe and efficacious in preclinical animal studies.
COVI-VAC was developed with Codagenix’s Synthetic Attenuated Virus Engineering (SAVE) platform that makes use of synthetic biology to re-code the genes of viruses into safe and stable vaccines.
COVI-VAC is designed to deliver a safe, live attenuated version of SARS-CoV-2 that may induce a more robust immune response and long-lasting cellular immunity against SARS-CoV-2 compared to other vaccines against the virus.
Dr. Rajeev Dhere, Executive Director of SIIPL, “We at SIIPL are pleased with the MHRA approval for initiating the first-in-human clinical trial for the novel intranasal product against COVID-19, developed by Codagenix in collaboration with SIIPL. The product is promising with many unique features and will make our fight against the virus stronger, and therefore, this news is surely welcoming.”
COVI-VAC has the potential to address many important logistical challenges to immunization against SARS-CoV-2 at a global scale.
As a single-dose, intranasally-delivered vaccine, COVI-VAC will not require a needle and syringe, nor ultra-low temperature freezers. COVI-VAC can be manufactured at large scale and supports ease of administration in a mass vaccination campaign.
Dose-esclation study
The Phase 1 trial of COVI-VAC is designed as a double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the safety and tolerability of a single dose of COVI-VAC given by nose drops.
The secondary objective of the study is to evaluate immunogenicity, or the vaccine’s ability to provoke an immune response, measured as neutralizing antibody, mucosal IgA and cellular immune responses.
![](https://theonlook.com/wp-content/uploads/2023/10/For-wordpress.jpg")
The trial will be conducted by hVIVO in London, United Kingdom a subsidiary of Open Orphan. Patient recruitment has started and dosing of the first trial participants will commence in the first week of January 2021.
(With inputs from The OnLook News Research Bureau)
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
Also read: Covid immunity lasts for many months, says study of healthcare workers
